Research Output per year
Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.
- 15 Similar Profiles
Breast Neoplasms
Medicine & Life Sciences
letrozole
Medicine & Life Sciences
Lymphocytes
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
Antibody-Dependent Cell Cytotoxicity
Medicine & Life Sciences
Silymarin
Medicine & Life Sciences
Disease-Free Survival
Medicine & Life Sciences
Antibodies
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Research Output 1973 2019
11
Citations
(Scopus)
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients
Lambertini, M., Campbell, C., Bines, J., Korde, L. A., Izquierdo, M., Fumagalli, D., Del Mastro, L., Ignatiadis, M., Pritchard, K., Wolff, A. C., Jackisch, C., Láng, I., Untch, M., Smith, I., Boyle, F., Xu, B., Barrios, C. H., Baselga, J., Moreno-Aspitia, A., Piccart, M. & 2 others, jan. 1 2019, In : Journal of the National Cancer Institute. 111, 1, p. 86-94 9 p.Research output: Article
Amenorrhea
Breast Neoplasms
Survival
Hormones
Therapeutics
14
Citations
(Scopus)
Efficacy of chemotherapy for ER-negative and ER-positive isolated locoregional recurrence of breast cancer: Final analysis of the CALOR trial
Wapnir, I. L., Price, K. N., Anderson, S. J., Robidoux, A., Martín, M., Nortier, J. W. R., Paterson, A. H. G., Rimawi, M. F., Láng, I., Baena-Cañada, J. M., Thürlimann, B., Mamounas, E. P., Geyer, C. E., Gelber, S., Coates, A. S., Gelber, R. D., Rastogi, P., Regan, M. M., Wolmark, N. & Aebi, S., ápr. 10 2018, In : Journal of Clinical Oncology. 36, 11, p. 1073-1079 7 p.Research output: Article
Estrogen Receptors
Breast Neoplasms
Recurrence
Drug Therapy
Disease-Free Survival
Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071)
the EORTC Gastrointestinal Tract Cancer Group, jan. 1 2018, (Accepted/In press) In : Cancer Chemotherapy and Pharmacology.Research output: Article
Stomach Neoplasms
Fluorescence In Situ Hybridization
Placebos
Fluorescence
Immunohistochemistry